[Brain imaging of Alzheimer' disease: state of the art and perspectives for clinicians]

Rev Med Suisse. 2016 Apr 20;12(515):795-8.
[Article in French]


To improve the clinical detection of Alzheimer's disease (AD) new diagnostic criteria have been proposed, based on biomarkers of synaptic dysfunction, AD-related neurodegeneration, and Aβ cerebral amyloidosis. Magnetic resonance imaging (MRI) and position emission tomography (PET) neuroimaging can be configured as powerful means for the detection of medial-temporal atrophy, reduced uptake of 18F-FDG PET or and increased retention of Aβ amyloid protein by amyloïd-PET. In this review, we will discuss these promising techniques that allow assessing in vivo AD pathology and help clinicians to better diagnose and follow-up patients, particularly in clinical trials using disease-modifying treatments.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / cerebrospinal fluid
  • Biomarkers / cerebrospinal fluid
  • Brain / pathology*
  • Fluorodeoxyglucose F18 / administration & dosage
  • Humans
  • Image Interpretation, Computer-Assisted
  • Magnetic Resonance Imaging* / methods
  • Neuroimaging / methods
  • Positron-Emission Tomography* / methods
  • Predictive Value of Tests
  • Radiopharmaceuticals / administration & dosage
  • Sensitivity and Specificity
  • tau Proteins / cerebrospinal fluid


  • Amyloid beta-Peptides
  • Biomarkers
  • Radiopharmaceuticals
  • tau Proteins
  • Fluorodeoxyglucose F18